المؤلفون: V. Amirjanova N., A. Karateev E., E. Pogozheva Y., A. Baranov A., V. Mazurov I., R. Samigullina R., O. Anoshenkova N., N. Lapkina A., T. Grineva Yu., E. Nasonov L., A. Lila M., В. Амирджанова Н., А. Каратеев Е., Е. Погожева Ю., А. Баранов А., В. Мазуров И., Р. Самигуллина Р., О. Аношенкова Н., Н. Лапкина А., Т. Гринева Ю., Е. Насонов Л., А. Лила М.

المساهمون: Исследование выполнялось в рамках фундаментальной темы ФГБНУ НИИР им. В.А.Насоновой «Контроль боли при ревматических заболеваниях: консервативная терапия и хирургические методы коррекции» № АААА-А19-119021190148-3. Авторы несут полную ответственность за предоставление окончательной версии рукописи в печать.

المصدر: Rheumatology Science and Practice; Vol 59, No 5 (2021); 571-577 ; Научно-практическая ревматология; Vol 59, No 5 (2021); 571-577 ; 1995-4492 ; 1995-4484

مصطلحات موضوعية: rheumatoid arthritis, upadacitinib, efficacy, quality of life, ревматоидный артрит, упадацитиниб, эффективность, качество жизни

وصف الملف: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/3077/2125; Насонов ЕЛ, Александрова ЕН, Новиков АА. Аутоиммунные ревматические заболевания: итоги и перспективы научных исследований. Научно-практическая ревматология. 2015;53(3):230-237.; Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76(6):960-977. doi:10.1136/annrheumdis-2016-210715; Taylor PC, Moore A, Vasilescu R, Alvir J, Tarallo M. A structured literature review of the burden of illness and unmet needs in patients with rheumatoid arthritis: A current perspective. Rheumatol Int.2016;36(5):685-695. doi:10.1007/s00296-015-3415-x; Baker KF, Isaacs JD. Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn’s disease and ulcerative colitis? Ann Rheum Dis. 2018;77(2):175-187. doi:10.1136/annrheumdis-2017-211555; Насонов ЕЛ. Фармакотерапия ревматоидного артрита: новая стратегия, новые мишени. Научно-практическая ревматология. 2017;55(4):409-419.; Schwartz DM, Kanno Y, Villarino A, Ward M, Gadina M, O’Shea JJ. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017;16(12):843-862. doi:10.1038/nrd.2017.201; Насонов ЕЛ, Лила АМ. Ингибиторы Янус-киназ при иммуновоспалительных ревматических заболеваниях: новые возможности и перспективы. Научно-практическая ревматология. 2019;57(1):8-16.; Насонов ЕЛ, Авдеева АС, Лила АМ. Эффективность и безопасность тофацитиниба при иммуновоспалительных ревматических заболеваниях (часть I). Научно-практическая ревматология. 2020;58(1):62-79. [Nasonov EL, Avdeeva AS, Lila AM. Efficacy and safety of tofacitinib for immune-mediated inflammatory rheumatic diseases (Part I). Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2020;58(1):62-79 (In Russ.)]. doi:10.14412/1995-4484-2020-62-79; Dhillon S. Tofacitinib: A review in rheumatoid arthritis. Drugs. 2017;77(18):1987-2001. doi:10.1007/s40265-017-0835-9; Насонов ЕЛ, Лила АМ. Барицитиниб: новые возможности фармакотерапии ревматоидного артрита и других иммуновоспалительных ревматических заболеваний. Научно-практическая ревматология. 2020;58(3):304-316.; Al-Salama ZT, Scott LJ. Baricitinib: A review in rheumatoid arthritis. Drugs. 2018;78(7):761-772. doi:10.1007/s40265-018-0908-4; Serhal L, Edwards CJ. Upadacitinib for the treatment of rheumatoid arthritis. Expert Rev Clin Immunol. 2019;15(1):13-25. doi:10.1080/1744666X.2019.1544892; Tanaka Y. A review of upadacitinib in rheumatoid arthritis. Mod Rheumatol. 2020;30(5):779-787. doi:10.1080/14397595.2020.1782049; Genovese MC, Fleischmann R, Combe B, Hall S, Rubbert-Roth A, Zhang Y, et al. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): A double-blind, randomised controlled phase 3 trial. Lancet. 2018;391(10139):2513-2524. doi:10.1016/S0140-6736(18)31116-4; Mysler E, Lizarraga A. Phase III trials of JAK1 selective inhibitors in rheumatoid arthritis. Rheumatology. 2021;60:17-23. doi:10.1093/rheumatology/keaa823; Fleischmann R, Pangan AL, Song IH, Mysler E, Bessette L, Peterfy C, et al. Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: Results of a phase III, double-blind, randomized controlled trial. Arthritis Rheumatol. 2019;71(11):1788-1800.doi:10.1002/art.41032; Smolen JS, Pangan AL, Emery P, Rigby W, Tanaka Y, Vargas JI, et al. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): A randomised, placebocontrolled, double-blind phase 3 study. Lancet.2019;393(10188):2303-2311. doi:10.1016/S0140-6736(19)30419-2; Strand V, Pope J, Tundia N, Friedman A, Camp HS, Pangan A, et al. Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease modifying antirheumatic drugs: Results from SELECT-NEXT. Arthritis Res Ther. 2019;21(1):272. doi:10.1186/s13075-019-2037-1; Strand V, Schiff M, Tundia N, Friedman A, Meerwein S, Pangan A, et al. Effects of upadacitinib on patient-reported outcomes: Results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs. Arthritis Res Ther. 2019;21(1):263. doi:10.1186/s13075-019-2059-8; Kapetanovic MC, Andersson M, Friedman A, Shaw T, Song Y, Aletaha D, et al. SAT0145 Efficacy and safety of upadacitinib monotherapy in MTX-naive patients with early active RA receiving treatment within 3 months of diagnosis: A post-hoc analysis of the SELECT-EARLY. Ann Rheum Dis. 2020;79:1011. doi:10.1136/annrheumdis-2020-eular.1431; Zigmond AS, Snaith RP. The Hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361-370. doi:10.1111/j.1600-0447.1983.tb09716.x; Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the Hospital anxiety and depression scale. An updated literature review. J Psychosom Res. 2002;52(2):69-77. doi:10.1016/s0022-3999(01)00296-3; Schwartz DM, Bonelli M, Gadina M, O’Shea JJ. Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nat Rev Rheumatol. 2016;12(1):25-36. doi:10.1038/nrrheum.2015.167; Firestein GS, McInnes IB. Immunopathogenesis of rheumatoid arthritis. Immunity. 2017;46(2):183-196. doi:10.1016/j.immuni.2017.02.006; Hosseini A, Gharibi T, Marofi F, Javadian M, Babaloo Z, Baradaran B. Janus kinase inhibitors: A therapeutic strategy for cancer and autoimmune diseases. J Cell Physiol. 2020;235(9):5903-5924. doi:10.1002/jcp.29593; Parmentier JM, Voss J, Graff C, Schwartz A, Argiriadi M, Friedman M, et al. In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494). BMC Rheumatol.2018;2:23. doi:10.1186/s41927-018-0031-x; Насонов ЕЛ, Лила АМ. Эффективность и безопасность упадацитиниба при ревматоидном артрите. Научно-практическая ревматология. 2020;58(5):532-543.; Rubbert-Roth A, Enejosa J, Pangan A, Haraoui B, Rischmueller M, Khan N, et al. Trial of upadacitinib or abatacept in rheumatoid arthritis. N Engl J Med. 2020;383(16):1511-1521. doi:10.1056/NEJMoa2008250; Kameda H, Takeuchi T, Yamaoka K, Oribe M, Kawano M, Zhou Y, et al. Efficacy and safety of upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): A placebocontrolled phase IIb/III study. Rheumatology (Oxford).2020;59(11):3303-3313. doi:10.1093/rheumatology/keaa084; Fleischmann RM, Genovese MC, Enejosa JV, Mysler E, Bessette L, Peterfy C, et al. Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response. Ann Rheum Dis. 2019;78(11):1454-1462. doi:10.1136/annrheumdis-2019-215764; Burmester GR, Kremer JM, Van den Bosch F, Kivitz A, Bessette L, Li Y, et al. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): A randomised, doubleblind, placebo-controlled phase 3 trial. Lancet. 2018;391(10139):2503-2512. doi:10.1016/S0140-6736(18)31115-2; https://rsp.mediar-press.net/rsp/article/view/3077

الاتاحة: https://rsp.mediar-press.net/rsp/article/view/3077
https://doi.org/10.47360/1995-4484-2021-571-577

المؤلفون: A. Karateev E., E. Pogozheva Yu., E. Filatova S., A. Lila M., V. Amirdjanova N., V. Nesterenko A., А. Каратеев Е., Е. Погожева Ю., Е. Филатова С., А. Лила М., В. Амирджанова Н., В. Нестеренко А.

المصدر: Rheumatology Science and Practice; Vol 58, No 4 (2020); 387-394 ; Научно-практическая ревматология; Vol 58, No 4 (2020); 387-394 ; 1995-4492 ; 1995-4484

مصطلحات موضوعية: acute pain, Diclofenac Potassium sachets, intramuscular Diclofenac injections, efficacy, safety, острая боль, диклофенак калия саше, внутримышечные инъекции диклофенака

وصف الملف: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/2926/2003; Насонов ЕЛ, Яхно НН, Каратеев АЕ и др. Общие принципы лечения скелетно-мышечной боли: междисциплинарный консенсус. Научно-практическая ревматология. 2016;54(3):247-265 https://doi.org/10.14412/1995- 4484-2016-247-265; Rajan J, Behrends M. Acute Pain in Older Adults: Recommendations for Assessment and Treatment. Anesthesiol Clin. 2019;37(3):507-520. doi:10.1016/j.anclin.2019.04.009; Dizdarevic A, Farah F, Ding J et al. A Comprehensive Review of Analgesia and Pain Modalities in Hip Fracture Pathogenesis. Curr Pain Headache Rep. 2019;23(10):72. doi:10.1007/s11916-019-0814-9; Nischal N, Arulraja E, Shaheen S. Pain Management for Orthopedic Injuries. Emerg Med Clin North Am. 2020;38(1):223-241. doi:10.1016/j.emc.2019.09.013; World Health Organization. Strengthening of palliative care as a component of integrated treatment throughout the life course. J Pain Palliat Care Pharmacother. 2014;28(2):130-4. doi:10.3109/15360288.2014.911801; Каратеев АЕ, Насонов ЕЛ, Ивашкин ВТ и др. Рациональное использование нестероидных противовоспалительных препаратов. Клинические рекомендации. Научно-практическая ревматология. 2018;56:1-29. https://doi.org/10.14412/1995-4484-2018-1-29; Probst M, Kühn J-P, Modeß C, et al. Muscle Injury After Intramuscular Administration of Diclofenac: A Case Report Supported by Magnetic Resonance Imaging. Drug Saf Case Rep. 2017;4(1):7. doi:10.1007/s40800-017-0049-9; Tarloff D, Lamacraft G, Joubert G. The Prevalence of Skin Scars in Patients Previously Given Intramuscular Diclofenac Injections Attending the Pain Clinic at Universitas Academic Hospital, Bloemfontein, South Africa. S Afr Med J. 2017;107(2):101-105. doi:10.7196/SAMJ.2017.v107i2.12012; Kadioglu H. Sciatic Nerve Injuries From Gluteal Intramuscular Injection According to Records of the High Health Council. Turk Neurosurg. 2018;28(3):474-478. doi:10.5137/1019-5149.JTN.19789-16.4; Lardelli P, Lermini L, Milani G, et al. Nicolau Syndrome Caused by Non-Steroidal Anti-Inflammatory Drugs: Systematic Literature Review. Int J Clin Pract. 2020;e13567. doi:10.1111/ijcp.13567; Rotman-Pikielny P, Eyal Y-L, Shoenfeld Y. Pyomyositis or “injectiositis”--Staphylococcus Aureus Multiple Abscesses Following Intramuscular Injections. Isr Med Assoc J. 2003;5(4):295-6; Каратеев АЕ. Эффективный контроль острой боли как важнейший элемент предупреждения ее перехода в хроническую: возможности применения нового препарата диклофенака калия. Эффективная фармакотерапия, 2019, 15 (4), 24-31; Tramèr MR, Williams JE, Carroll D, et al. Comparing analgesic efficacy of non-steroidal anti-inflammatory drugs given by different routes in acute and chronic pain: a qualitative systematic review. Acta Anaesthesiol Scand. 1998; 42(1): 71-79; Schwartz N, Turturro M, Istvan D, Larkin G. Patients’ Perceptions of Route of Nonsteroidal Anti-Inflammatory Drug Administration and Its Effect on Analgesia. Acad Emerg Med. 2000; 7(8):857-61. doi:10.1111/j.1553-2712.2000.tb02061.x; Braaten K, Hurwitz S, Fortin J, Goldberg A. Intramuscular Ketorolac Versus Oral Ibuprofen for Pain Relief in FirstTrimester Surgical Abortion: A Randomized Clinical Trial. Contraception. 2014; 89(2):116-21. doi:10.1016/j.contraception.2013.10.009; Neighbor M, Puntillo K. Intramuscular Ketorolac vs Oral Ibuprofen in Emergency Department Patients With Acute Pain. Acad Emerg Med. 1998;5(2):118-22. doi:10.1111/j.1553-2712.1998.tb02595.x; Pavelka K. A comparison of the therapeutic efficacy of diclofenac in osteoarthritis: a systematic review of randomised controlled trials. Curr Med Res Opin. 2012;28(1):163-78. doi:10.1185/03007995.2011.649848; da Costa BR, Reichenbach S, Keller N, et al. Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis. Lancet. 2016 21;387(10033):2093-105. doi:10.1016/S0140-6736(16)30002-2; van Walsem A, Pandhi S, Nixon RM, et al. Relative benefit-risk comparing diclofenac to other traditional non-steroidal antiinflammatory drugs and cyclooxygenase-2 inhibitors in patients with osteoarthritis or rheumatoid arthritis: a network metaanalysis. Arthritis Res Ther. 2015;17:66. doi:10.1186/s13075-015-0554-0; Moore RA, Derry S. Diclofenac Potassium in Acute Postoperative Pain and Dysmenorrhoea: Results from Comprehensive Clinical Trial Reports. Pain Res Manag. 2018;2018:9493413. doi:10.1155/2018/9493413; Marzo A, Dal Bo L, Verga F, et al. Pharmacokinetics of diclofenac after oral administration of its potassium salt in sachet and tablet formulations. Arzneimittelforschung. 2000;50(1):43-47; Reiner V, Reiner A, Reiner G, Conti M. Increased absorption rate of diclofenac from fast acting formulations containing its potassium salt. Arzneimittelforschung. 2001; 51(11):885-90.; Gazal G, Al-Samadani KH. Comparison of paracetamol, ibuprofen, and diclofenac potassium for pain relief following dental extractions and deep cavity preparations. Saudi Med J. 2017; 38(3):284-291. doi:10.15537/smj.2017.3.16023; Каратеев АЕ, Погожева ЕЮ, Лила АМ и др. Ретроспективное наблюдательное исследование ДРАйВ (Действенная и Рациональная Анальгезия: Выбор). РМЖ. 2019; 9: 62-66.; Zieglgänsberger W. Substance P and Pain Chronicity. Cell Tissue Res. 2019; 375(1):227-241. doi:10.1007/s00441-018-2922-y; Singh J, Noorbaloochi S., Knutson S. Cytokine and Neuropeptide Levels Are Associated With Pain Relief in Patients With Chronically Painful Total Knee Arthroplasty: A Pilot Study. BMC Musculoskelet Disord. 2017;18(1):17. doi:10.1186/s12891-016-1375-2; Mohammed N, Allam H, Elghoroury E, et al. Evaluation of Serum Beta-Endorphin and Substance P in Knee Osteoarthritis Patients Treated by Laser Acupuncture. J Complement Integr Med. 2018; 15(2). j/jcim.2018.15.issue-2/jcim-2017-0010/jcim2017-0010.xml. doi:10.1515/jcim-2017-0010; Bianchi M, Broggini M, Balzarini P, et al. Effects of Nimesulide on Pain and on Synovial Fluid Concentrations of Substance P, interleukin-6 and interleukin-8 in Patients With Knee Osteoarthritis: Comparison With Celecoxib. Int J Clin Pract. 2007 ;61(8):1270-7. doi:10.1111/j.1742-1241.2007.01453.x; Miller G, Nicklas B, Loeser R. Inflammatory Biomarkers and Physical Function in Older, Obese Adults With Knee Pain and Self-Reported Osteoarthritis After Intensive Weight-Loss Therapy. J Am Geriatr Soc. 2008; 56(4):644-51. doi:10.1111/j.1532-5415.2007.01636.x; Esme H, Kesli R, Apiliogullari B, et al. Effects of Flurbiprofen on CRP, TNF-α, IL-6, and Postoperative Pain of Thoracotomy. Int J Med Sci. 2011; 8(3):216-21. doi:10.7150/ijms.8.216; Phillips T, Childs A, Dreon D, et al. A Dietary Supplement Attenuates IL-6 and CRP After Eccentric Exercise in Untrained Males. Med Sci Sports Exerc. 2003; 35(12):2032-7. doi:10.1249/01.MSS.0000099112.32342.10; Thudium C, Löfvall H, Karsdal M, et al. Protein Biomarkers Associated With Pain Mechanisms in Osteoarthritis. J Proteomics. 2019;190:55-66. doi:10.1016/j.jprot.2018.04.030; https://rsp.mediar-press.net/rsp/article/view/2926

الاتاحة: https://rsp.mediar-press.net/rsp/article/view/2926
https://doi.org/10.47360/1995-4484-2020-387-394

المؤلفون: A. Karateev E., E. Pogozheva Yu., M. Sukhareva L., A. Lila M., A. Ivanov V., I. Osnovina P., O. Shchashkova V., S. Borisova V., N. Larinsky Е., Yu. Israelyan A., S. Afoshin А., T. Bondarenko P., E. Repchanskaya А., L. Chernyavskaya A., S. Pupina P., T. Darmova V., А. Каратеев Е., Е. Погожева Ю., М. Сухарева Л., А. Лила М., А. Иванов В., И. Основина П., О. Щашкова В., С. Борисова В., Н. Ларинский С., Ю. Исраелян А., С. Афошин А., Т. Бондаренко П., Э. Репчанская А., Л. Чернявская А., С. Пупина П., Т. Дармова В.

المصدر: Rheumatology Science and Practice; Vol 58, No 1 (2020); 55-61 ; Научно-практическая ревматология; Vol 58, No 1 (2020); 55-61 ; 1995-4492 ; 1995-4484

مصطلحات موضوعية: osteoarthritis, magnet therapy, placebo-controlled study, efficiency, safety, остеоартрит, магнитотерапия, плацебоконтролируемое исследование, эффективность, безопасность

وصف الملف: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/2844/1930; Насонов ЕЛ, редактор. Российские клинические рекомендации. Ревматология. Москва: ГЭОТАР-Медиа; 2017. 446 с. ISBN 978-5-9704-4261-6; Алексеева ЛИ, Таскина ЕА, Кашеварова НГ. Остеоартрит: эпидемиология, классификация, факторы риска и прогрессирования, клиника, диагностика и лечение. Современная ревматология. 2019;13(2):9-21. doi:10.14412/1996-7012-2019-2-9-21; Geenen R, Overman CL, Christensen R, et al. EULAR recommendations for the health professional's approach to pain management in inflammatory arthritis and osteoarthritis. Ann Rheum Dis. 2018 Jun;77(6):797-807. doi:10.1136/annrheumdis-2017-212662. Epub 2018 May 3.; Ganesan K, Gengadharan AC, Balachandran C, et al. Low frequency pulsed electromagnetic field — a viable alternative therapy for arthritis. Indian JExp Biol. 2009 Dec;47(12):939-48.; Pittler MH. Static magnets for reducing pain. MMW Fortschr Med. 2009 Jan 22;151(3-4):33, 35.; Redeker JI, Schmitt B, Grigull NP, et al. Effect of electromagnetic fields on human osteoarthritic and non-osteoarthritic chondrocytes. BMC Complement Atern Med. 2017 Aug 14;17(1):402. doi:10.1186/s12906-017-1868-z; Yang X, He H, Zhou Y, et al. Pulsed electromagnetic field at different stages of knee osteoarthritis in rats induced by low-dose monosodium iodoacetate: Effect on subchondral trabecular bone microarchitecture and cartilage degradation. Bioelectromagnetics. 2017 Apr;38(3):227-38. doi:10.1002/bem.22028. Epub 2016 Dec 27.; Yang X, He H, Gao Q, He C. Pulsed electromagnetic field improves subchondral bone microstructure in knee osteoarthritis rats through a Wnt/p-catenin signaling-associated mechanism. Bioelectromagnetics. 2018 Feb;39(2):89-97. doi:10.1002/bem.22106. Epub 2017 Dec 18.; Li S, Yu B, Zhou D, et al. Electromagnetic fields for treating osteoarthritis. Cochrane Database Syst Rev. 2013 Dec 14;(12):CD003523. doi:10.1002/14651858.CD003523.pub2; Ryang We S, Koog YH, Jeong KI, Wi H. Effects of pulsed electromagnetic field on knee osteoarthritis: a systematic review. Rheumatology (Oxford). 2013 May;52(5):815-24. doi:10.1093/rheumatology/kes063. Epub 2012 Apr 13.; Wu Z, Ding X, Lei G, et al. Efficacy and safety of the pulsed electromagnetic field in osteoarthritis: a meta-analysis. BMJ Open. 2018 Dec 14;8(12):e022879. doi:10.1136/bmjopen-2018-022879; Бяловский Ю, Иванов А, Лякина О, Ракитина И. Эффективность импульсной магнитотерапии аппаратом «АЛМАГ+» в комплексном лечении больных остеоартрозом коленных суставов. Врач. 2019;30(6):67-71 [. doi:10.29296/25877305-2019-06-16; Бяловский Ю, Секирин А, Смирнова С. Эффективность низкочастотной магнитотерапии «бегущим» магнитным полем в комплексном лечении коксартроза. Врач. 2018;29(3):75-9. doi:10.29296/25877305-2018-03-19; Ларинский Н, Ларинская И, Бяловский Ю, Иванов А. Оценка эффективности низкочастотной магнитотерапии от аппарата АЛМАГ+ в комплексном лечении дорсопатии (остеохондроз позвоночника, грыжи дисков позвоночника). Врач. 2019;30(4):69-73. doi:10.29296/25877305-2019-04-13; Bagnato GL, Miceli G, Marino N, et al. Pulsed electromagnetic fields in knee osteoarthritis: a double blind, placebo-controlled, randomized clinical trial. Rheumatology (Oxford). 2016 Apr;55(4):755-62. doi:10.1093/rheumatology/kev426. Epub 2015 Dec 24.; Wuschech H, von Hehn U, Mikus E, Funk RH. Effects of PEMF on patients with osteoarthritis: Results of a prospective, placebo-controlled, double-blind study. Bioelectromagnetics. 2015 Dec;36(8):576-85. doi:10.1002/bem.21942. Epub 2015 Nov 12.; Nelson FR, Zvirbulis R, Pilla AA. Non-invasive electromagnetic field therapy produces rapid and substantial pain reduction in early knee osteoarthritis: a randomized double-blind pilot study. RheumatolInt. 2013 Aug;33(8):2169-73. doi:10.1007/s00296-012-2366-8. Epub 2012 Mar 27.; Altman RD, Devji T, Bhandari M, et al. Clinical benefit of intraarticular saline as a comparator in clinical trials of knee osteoarthritis treatments: A systematic review and meta-analysis of randomized trials. Semin Arthritis Rheum. 2016 Oct;46(2):151-9. doi:10.1016/j.semarthrit.2016.04.003. Epub 2016 Apr 27.; Huang Z, Chen J, Hu QS, et al. Meta-analysis of pain and function placebo responses in pharmacological osteoarthritis trials. Arthritis Res Ther. 2019 Jul 15;21(1):173. doi:10.1186/s13075-019-1951-6; Zhang W. The powerful placebo effect in osteoarthritis. Clin Exp Rheumatol. 2019 Sep-Oct;37 Suppl 120(5):118-23. Epub 2019 Oct 15.; https://rsp.mediar-press.net/rsp/article/view/2844

الاتاحة: https://rsp.mediar-press.net/rsp/article/view/2844
https://doi.org/10.14412/1995-4484-2020-55-61

المؤلفون: V. Amirdzhanova N., A. Karateev E., E. Pogozheva Yu., В. Амирджанова Н., А. Каратеев Е., Е. Погожева Ю.

المصدر: Rheumatology Science and Practice; Vol 56, No 5 (2018); 549-555 ; Научно-практическая ревматология; Vol 56, No 5 (2018); 549-555 ; 1995-4492 ; 1995-4484 ; undefined

مصطلحات موضوعية: preoperative preparation, arthroplasty, rheumatic diseases, disease-modifying antiinflammatory drugs, biological agents, glucocorticoids, предоперационная подготовка, эндопротезирование суставов, ревматические заболевания, ба- зисные противовоспалительные препараты, генно-инженерные биологические препараты, глюкокортикоиды

وصف الملف: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/2616/1750; Goodman SM, Springer B, Guyatt G, et al. 2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty. Arthritis Rheum. 2017;69(8):1538-51. doi:10.1002/art.40149; Strand V, Singh JA. Improved health-related quality of life with effective disease-modifying antirheumatic drugs: evidencefrom randomized controlled trials. Am J Manag Care. 2008;14:234-54.; Ravi B, Croxford R, Reichmann WM, et al. The changing demographics of total joint arthroplasty recipients in the United States and Ontario from 2001 to 2007. Best Pract Res Clin Rheumatol. 2012;26:637-47. doi:10.1016/j.berh.2012.07.014; Mertelsmann-Voss C, Lyman S, Pan TJ, et al. Arthroplasty rates are increased among US patients with systemic lupus erythematosus: 1991-2005. J Rheumatol. 2014;41:867-74. doi:10.3899/jrheum.130617; Mertelsmann-Voss C, Lyman S, Pan TJ, et al. US trends in rates of arthroplasty for inflammatory arthritis including rheumatoid arthritis, juvenile idiopathic arthritis, and spondyloarthritis. Arthritis Rheum. 2014;66:1432-9. doi:10.1002/art.38384; Nikiphorou E, Carpenter L, Morris S, et al. Hand and foot surgery rates in rheumatoid arthritis have declined from 1986 to 2011, but large-joint replacement rates remain unchanged: results from two UK inception cohorts. Arthritis Rheum. 2014;66:1081-9. doi:10.1002/art.38344; Sokka T, Kautiainen H, Hannonen P. Stable occurrence of knee and hip total joint replacement in Central Finland between 1986 and 2003: an indication of improved longterm outcomes of rheumatoid arthritis. Ann Rheum Dis. 2007;66:341-4. doi:10.1136/ard.2006.057067; Ravi B, Croxford R, Hollands S, et al. Increased risk of complications following total joint arthroplasty in patients with rheumatoid arthritis. Arthritis Rheum. 2014;66:254-63. doi:10.1002/art.38231; Lin JA, Liao CC, Lee YJ, et al. Adverse outcomes after major surgery in patients with systemic lupus erythematosus: a nationwide population-based study. Ann Rheum Dis. 2014;73:1646-51. doi:10.1136/annrheumdis-2012-202758; Singh JA, Inacio MC, Namba RS, Paxton EW. Rheumatoid arthritis is associated with higher ninety-day hospital readmission rates compared to osteoarthritis after hip or knee arthroplasty: a cohort study. Arthritis Care Res (Hoboken). 2015;67:718-24. doi:10.1002/acr.22497; Roberts JE, Mandl LA, Su EP, et al. Patients with systemic lupus erythematosus have increased risk of short-term adverse events after total hip arthroplasty. J Rheumatol. 2016;43:1498-502. doi:10.3899/jrheum.151373; Насонов ЕЛ, Мазуров ВИ, Каратеев ДЕ и др. Проект рекомендаций по лечению ревматоидного артрита Общероссийской общественной организации «Ассоциация ревматологов России» – 2014 (часть 1). Научно-практическая ревматология. 2014;52(5):477-95 [Nasonov EL, Mazurov VI, Karateev DE, et al. Spondyloarthritis: Evolution of a concept. Project: recommendations on treatment of rheumatoid arthritis developed by All-Russian Public organization «Association of Rheumatologists of Russia» – 2014 (part 1). Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2014;52(5):477-94 (In Russ.)]. doi:10.14412/1995-4484-2014-477-494; Goodman SM, Ramsden-Stein DN, Huang WT, et al. Patients with rheumatoid arthritis are more likely to have pain and poor function after total hip replacements than patients with osteoarthritis. J Rheumatol. 2014;41:1774-80. doi:10.3899/jrheum.140011; Goodman SM, Johnson B, Zhang M, et al. Patients with rheumatoid arthritis have similar excellent outcomes after total knee replacement compared with patients with osteoarthritis. J Rheumatol. 2016;43:46-53. doi:10.3899/jrheum.150525; LoVerde ZJ, Mandl LA, Johnson BK, et al. Rheumatoid arthritis does not increase risk of short-term adverse events after total knee arthroplasty: a retrospective case-control study. J Rheumatol. 2015;42:1123-30. doi:10.3899/jrheum.141251; Johnson BK, Goodman SM, Alexiades MM, et al. Patterns and associated risk of perioperative use of anti-tumor necrosis factor in patients with rheumatoid arthritis undergoing total knee replacement. J Rheumatol. 2013;40:617-23. doi:10.3899/jrheum.121171; Berbari EF, Osmon DR, Lahr B, et al. The Mayo prosthetic joint infection risk score: implication for surgical site infection reporting and risk stratification. Infect Control Hosp Epidemiol. 2012;33:774-81. doi:10.1086/666641; Bongartz T, Halligan CS, Osmon DR, et al. Incidence and risk factors of prosthetic joint infection after total hip or knee replacement in patients with rheumatoid arthritis. Arthritis Rheum. 2008;59:1713-20. doi:10.1002/art.24060; Goodman SM, Menon I, Christos PJ, et al. Management of perioperative tumour necrosis factor a inhibitors in rheumatoid arthritis patients undergoing arthroplasty: a systematic review and metaanalysis. Rheumatology (Oxford). 2016;55:573-82.; Au K, Reed G, Curtis JR, et al. High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70:785-91.doi:10.1136/ard.2010.128637; Doran MF, Crowson CS, Pond GR, et al. Predictors of infection in rheumatoid arthritis. Arthritis Rheum. 2002;46:2294-300. doi:10.1002/art.10529; Kurtz SM, Lau E, Watson H, et al. Economic burden of periprosthetic joint infection in the United States. J Arthroplasty. 2012;Suppl 27:61-5. doi:10.1016/j.arth.2012.02.022; Centers for Disease Control and Prevention. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices. MMWR. 2011;60:22-3.; Salmon JE, Roman MJ. Subclinical atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus. Am J Med. 2008;Suppl 1:S3-8. doi:10.1016/j.amjmed.2008.06.010; Периоперационное ведение пациентов с ревматоидным артритом, нуждающихся в эндопротезировании крупных суставов нижних конечностей. В кн.: Насонов ЕЛ, редактор. Российские клинические рекомендации «Ревматология». Москва: ГЭОТАР-Медиа; 2017. С. 360-70 [Perioperative management of patients with rheumatoid arthritis who need endoprosthetics of large joints of lower extremities. In: Nasonov EL, editor. Rossiyskie klinicheskie rekomendatsii «Revmatologiya» [Russian Clinical Recommendations «Rheumatology»]. Moscow: GEOTAR-Media; 2017. P. 360-70 (In Russ.)].; Амирджанова ВН, Макаров МА, Бялик ЕИ и др. Периоперационное ведение больных ревматоидным артритом. Научно-практическая ревматология. 2014;52(4):366-76 [Amirdzhanova VN, Makarov MA, Byalik EI, et al. Perioperative; management of patients with rheumatoid arthritis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2014;52(4):366-75 (In Russ.)]. doi:10.14412/1995-4484-2014-366-375; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, et al.; ACCF/AHA focused update on perioperative b blockade incorporated into the ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery. J Am Coll Cardiol. 2009;54:e13-118. doi:10.1016/j.jacc.2009.07.010; Fleisher LA, Beckman JA, Brown KA, et al. 2009 ACCF/AHA focused update on perioperative b blockade incorporated into the ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. Circulation. 2009;120:e169-276. doi:10.1161/CIRCULATIONAHA.109.192690; Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed. American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141 Suppl 2:e278S-325S.; Jacobs JJ, Mont MA, Bozic KJ, et al. American Academy of Orthopaedic Surgeons clinical practice guideline on: preventing venous thromboembolic disease in patients undergoing elective hip and knee arthroplasty. J Bone Joint Surg Am. 2012;94:746-7. doi:10.2106/JBJS.9408.EBO746; Савенкова НА. Амирджанова ВН, Макаров СА и др. Отменять ли базисную терапию больным ревматоидным артритом перед эндопротезированием суставов? Научно-практическая ревматология. 2011;49(5):46-50 [Savenkova NA; Amirdzhanova VN, Makarov SA, et al. Should disease-modifying therapy be stopped in patients with rheumatoid arthritis before endoprosthetic joint replacement? Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2011;49(5):46-50 (In Russ.)]. doi:10.14412/1995-4484-2011-1460; Strand V, Ahadieh S, French J, et al. Systematic review and metaanalysis of serious infections with tofacitinib and biologic diseasemodifying antirheumatic drug treatment in rheumatoid arthritis clinical trials. Arthritis Res Ther. 2015;17:362. doi:10.1186/s13075-015-0880-2; Singh JA, Cameron C, Noorbaloochi S, et al. Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. Lancet. 2015;386:258-65. doi:10.1016/S0140-6736(14)61704-9; Maxwell LJ, Zochling J, Boonen A, et al. TNF-a inhibitors for ankylosing spondylitis. Cochrane Database Syst Rev. 2015;4:CD005468.; Ito H, Kojima M, Nishida K, et al. Postoperative complications in patients with rheumatoid arthritis using a biological agent: a systematic review and meta-analysis. Mod Rheumatol. 2015;25:672-8. doi:10.3109/14397595.2015.1014302; Lopez-Olivo MA, Amezaga Urruela M, McGahan L, et al. Rituximab for rheumatoid arthritis. Cochrane Database Syst Rev. 2015;1:CD007356.; Ruiz Garcia V, Jobanputra P, Burls A, et al. Certolizumab pegol (CDP870) for rheumatoid arthritis in adults. Cochrane Database Syst Rev. 2014;9:CD007649.; Song GG, Bae SC, Lee YH. Efficacy and safety of tofacitinib for active rheumatoid arthritis with an inadequate response to methotrexate or disease-modifying antirheumatic drugs: a metaanalysis of randomized controlled trials. Korean J Intern Med. 2014;29:656-63. doi:10.3904/kjim.2014.29.5.656; Cohen S, Radominski SC, Gomez-Reino JJ, et al. Analysis of infections and all-cause mortality in phase II, phase III, and longterm extension studies of tofacitinib in patients with rheumatoid arthritis. Arthritis Rheum. 2014;66:2924-37. doi:10.1002/art.38779; Michaud TL, Rho YH, Shamliyan T, et al. The comparative safety of tumor necrosis factor inhibitors in rheumatoid arthritis: a metaanalysis update of 44 trials. Am J Med. 2014;127:1208-32. doi:10.1016/j.amjmed.2014.06.012; Borba HH, Wiens A, de Souza TT, et al. Efficacy and safety of biologic therapies for systemic lupus erythematosus treatment: systematic review and meta-analysis. BioDrugs 2014;28:211-28. doi:10.1007/s40259-013-0074-x; He Y, Wong AY, Chan EW, et al. Efficacy and safety of tofacitinib in the treatment of rheumatoid arthritis: a systematic review and meta-analysis. BMC Musculoskelet Disord. 2013;14:298. doi:10.1186/1471-2474-14-298; Lethaby A, Lopez-Olivo MA, Maxwell L, et al. Etanercept for the treatment of rheumatoid arthritis. Cochrane Database Syst Rev. 2013;5:CD004525.; Machado MA, Barbosa MM, Almeida AM, et al. Treatment of ankylosing spondylitis with TNF blockers: a meta-analysis. Rheumatol Int. 2013;33:2199-213. doi:10.1007/s00296-013-2772-6; Li ZH, Zhang Y, Wang J, Shi ZJ. Etanercept in the treatment of ankylosing spondylitis: a meta-analysis of randomized, doubleblind, placebo-controlled clinical trials, and the comparison of the Caucasian and Chinese population. Eur J Orthop Surg Traumatol. 2013;23:497-506. doi:10.1007/s00590-012-1035-7; Schoels MM, van der Heijde D, Breedveld FC, et al. Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and metaanalysis informing a consensus statement. Ann Rheum Dis. 2013;72:583-9. doi:10.1136/annrheumdis-2012-202470; Lan L, Han F, Chen JH. Efficacy and safety of rituximab therapy for systemic lupus erythematosus: a systematic review and metaanalysis. J Zhejiang Univ Sci B. 2012;13:731-44. doi:10.1631/jzus.B1200057; Dommasch ED, Abuabara K, Shin DB, et al. The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials. J Am Acad Dermatol. 2011;64:1035- 50. doi:10.1016/j.jaad.2010.09.734; Campbell L, Chen C, Bhagat SS, et al. Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials. Rheumatology (Oxford). 2011;50:552-62. doi:10.1093/rheumatology/keq343; Lee YH, Bae SC, Song GG. The efficacy and safety of rituximab for the treatment of active rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials. Rheumatol Int. 2011;31:1493-9. doi:10.1007/s00296-010-1526-y; Katikireddi VS, Whittle SL, Hill CL. Tumour necrosis factor inhibitors and risk of serious infection in rheumatoid arthritis. Int J Rheum Dis. 2010;13:12-26. doi:10.1111/j.1756-185X.2009.01457.x; Wiens A, Venson R, Correr CJ, et al. Meta-analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis. Pharmacotherapy. 2010;30:339-53. doi:10.1592/phco.30.4.339; Storage SS, Agrawal H, Furst DE. Description of the efficacy and safety of three new biologics in the treatment of rheumatoid arthritis. Korean J Intern Med. 2010;25:1-17. doi:10.3904/kjim.2010.25.1.1; An MM, Zou Z, Shen H, et al. The addition of tocilizumab to DMARD therapy for rheumatoid arthritis: a meta-analysis of randomized controlled trials. Eur J Clin Pharmacol. 2010;66:49-59. doi:10.1007/s00228-009-0754-0; Wiens A, Correr CJ, Pontarolo R, et al. A systematic review and meta-analysis of the efficacy and safety of etanercept for treating rheumatoid arthritis. Scand J Immunol. 2009;70:337-44. doi:10.1111/j.1365-3083.2009.02296.x; Fouque-Aubert A, Jette-Paulin L, Combescure C, et al. Serious infections in patients with ankylosing spondylitis with and without TNF blockers: a systematic review and meta-analysis of randomised placebocontrolled trials. Ann Rheum Dis. 2010;69:1756-61. doi:10.1136/ard.2008.098822; Leombruno JP, Einarson TR, Keystone EC. The safety of antitumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis. 2009;68:1136-45. doi:10.1136/ard.2008.091025; Alonso-Ruiz A, Pijoan JI, Ansuategui E, et al. Tumor necrosis factor a drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety. BMC Musculoskelet Disord. 2008;9:52. doi:10.1186/1471-2474-9-52; Saad AA, Symmons DP, Noyce PR, Ashcroft DM. Risks and benefits of tumor necrosis factor-a inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials. J Rheumatol. 2008;35:883-90.; Gartlehner G, Hansen RA, Jonas BL, et al. The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. J Rheumatol. 2006;33:2398-408.; Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295:2275-85. doi:10.1001/jama.295.19.2275; Fleischmann R, Baumgartner SW, Weisman MH, et al. Long term safety of etanercept in elderly subjects with rheumatic diseases. Ann Rheum Dis. 2006;65:379-84. doi:10.1136/ard.2005.035287; Capogrosso Sansone A, Mantarro S, Tuccori M, et al. Safety profile of certolizumab pegol in patients with immune-mediated inflammatory diseases: a systematic review and meta-analysis. Drug Safety. 2015;38:869-88. doi:10.1007/s40264-015-0336-2; Tarp S, Furst DE, Luta G, et al. Risk of serious adverse effects associated with different biological and targeted synthetic diseasemodifying anti-rheumatic drugs in patients with rheumatoid arthritis: a systematic review and meta-analysis of randomised trials [abstract]. Ann Rheum Dis. 2015;74 Suppl 2:176-7.; De la Forest M, Brugneaux J, Utard G, Salliot C. Safety of anti-TNFs in RA patients in real life: results from a systematic literature review and meta-analyses from biologic registers [abstract]. Ann Rheum Dis. 2015;74 Suppl 2:702. doi:10.1136/annrheumdis-2015-eular.2781; Hochberg M, Janssen K, Broglio K, et al. Comparison of abatacept and other biologic DMARDs for the treatment of rheumatoid arthritis patients: a systematic literature review and network metaanalysis [abstract]. Ann Rheum Dis. 2014;73 Suppl 2:676. doi:10.1136/annrheumdis-2014-eular.5331; Tarp S, Tarp U, Andersen LS, et al. Serious adverse events associated with using biological agents to treat rheumatic diseases: network meta-analysis from a national guideline panel [abstract]. Arthritis Rheum. 2013;65 Suppl:S997-8.; He Y, Wong A, Chan E, et al. Safety of tofacitinib in the treatment of rheumatoid arthritis: a systematic review and meta-analysis. Drug Safety. 2013;36:852-3.; Singh JA, Wells G, Christensen R, et al. Risk of cancer, serious lung infections and death with biologics: a systematic review and network meta-analysis of randomized controlled trials (RCTs) [abstract]. Ann Rheum Dis. 2013;72:A74. doi:10.1136/annrheumdis-2013-eular.276; Ahadieh S, Checchio T, Tensfeldt T, et al. Meta-analysis of malignancies, serious infections, and serious adverse events with tofacitinib or biologic treatment in rheumatoid arthritis clinical trials. J Pharmacokinetics Pharmacodynamics. 2013;40:S93-4.; Lin T, Shamliyan T, Choi H, et al. The safety of anti-TNF biologic agents in rheumatoid arthritis: a metaanalysis of 35 RCTs [abstract]. Arthritis Rheum. 2012;64 Suppl:S1854.; Venson R, Wiens A, Correr CJ, Pontarolo R. Efficacy, safety and tolerability of using abatacept for the treatment of rheumatoid arthritis. Brazil J Pharm Sci. 2012;48:781-91. doi:10.1590/S1984-82502012000400022; Cormier H, Barnetche T, Schaeverbeke T. The risk of serious infection with and without anti-TNF therapy in rheumatoid arthritis and ankylosing spondylitis: a metaanalysis [abstract]. Arthritis Rheum. 2011;63 Suppl:S878.; Dommasch E, Troxel A, Shin D, et al. The safety of tumor necrosis factor antagonists in patients with psoriatic disease: a systematic review and metaanalysis of randomized controlled trials. J Am Acad Dermatol. 2011;64:AB8. doi:10.1016/j.jaad.2010.09.734; Rieder S, Thompson A, Pope J. Anti-TNF therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: a meta-analysis of randomized controlled trials. J Rheumatol. 2010;37:1343.; Powers J, Martin R. Incidence of serious infectious events with methotrexate treatment: metaanalysis of randomized controlled trials. J Am Acad Dermatol. 2010;62:AB4.; Volkmann ER, Agrawal H, Maranian P, Furst DE. Rituximab for rheumatoid arthritis: a meta-analysis and systematic review. Clin Med. 2010;2:749-60.; Kaine JL. Abatacept for the treatment of rheumatoid arthritis: a review. Curr Ther Res. 2007;68:379-99. doi:10.1016/j.curtheres. 2007.12.001; Nestorov I. Clinical pharmacokinetics of TNF antagonists: how do they differ? Semin Arthritis Rheum. 2005;34 Suppl 1:12-8. doi:10.1016/j.semarthrit.2005.01.004; Jinesh S. Pharmaceutical aspects of anti-inflammatory TNFblocking drugs. Inflammopharmacology. 2015;23:71-7. doi:10.1007/s10787-015-0229-0; Weisman MH, Moreland LW, Furst DE, et al. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human antitumor necrosis factor-a monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. Clin Ther. 2003;25:1700-21. doi:10.1016/S0149-2918(03)80164-9; Breedveld F, Agarwal S, Yin M, et al. Rituximab pharmacokinetics in patients with rheumatoid arthritis: B-cell levels do not correlate with clinical response. J Clin Pharmacol. 2007;47:1119-28. doi:10.1177/0091270007305297; Погожева ЕЮ, Амирджанова ВН, Макаров СА, Насонов ЕЛ. Осложнения после эндопротезирования суставов у пациентов, получающих генно-нженерные биологические препараты. Научно-практическая ревматология. 2012;50(3):43-8 [Pogozheva EYu, Amirdzhanova VN, Makarov SA, Nasonov EL. Complications after endoprosthetic joint replacement in patients receiving genetically engineered biological agents. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2012;50(3):43-8 (In Russ.)]. doi:10.14412/1995-4484-2012-708; Tarp S, Furst DE, Maarten B, et al. Risk of serious adverse effects of biological and targeted drugs in patients with rheumatoid arthritis: a systematic review meta-analysis. Rheumatology (Oxford). 2017;56:417-25.; Ramos-Casals M, Soto MJ, Cuadrado MJ, Khamashta MA. Rituximab in systemic lupus erythematosus: a systematic review of off-label use in 188 cases. Lupus. 2009;18:767-76. doi:10.1177/0961203309106174; Murray E, Perry M. Off-label use of rituximab in systemic lupus erythematosus: a systematic review. Clin Rheumatol. 2010;29:707-16. doi:10.1007/s10067-010-1387-5; Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebocontrolled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63:3918-30. doi:10.1002/art.30613; Ahadieh S, Checchio T, Tensfeldt T, et al. Meta-analysis of malignancies, serious infections, and serious adverse events with tofacitinib or biologic treatment in rheumatoid arthritis clinical trials [abstract]. Arthritis Rheum. 2012;64(10 Suppl):S726.; Boyle DL, Soma K, Hodge J, et al. The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signaling in rheumatoid arthritis. Ann Rheum Dis. 2015;74:1311-6. doi:10.1136/annrheumdis-2014-206028; Marik PE, Varon J. Requirement of perioperative stress doses of corticosteroids: a systematic review of the literature. Arch Surg. 2008;143:1222-6. doi:10.1001/archsurg.143.12.1222; Harpaz R, Ortega-Sanchez I, Seward J. Prevention of herpes zoster: recommendation of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2008;57:1-30.; Somayaji R, Barnabe C, Martin L. Risk factors for infection following total joint arthroplasty in rheumatoid arthritis. Open Rheumatol J. 2013;7:119-24. doi:10.2174/1874312920131210005; https://rsp.mediar-press.net/rsp/article/view/2616

الاتاحة: https://rsp.mediar-press.net/rsp/article/view/2616
https://doi.org/10.14412/1995-4484-2018-549-555

المؤلفون: A. Potapova, A. Karateev, E. Pogozheva, E. Matianova, A. Bobkova, A. Semashko, E. Filatova, V. Amirdzhanova, E. Zotkin, A. Lila

المصدر: Annals of the Rheumatic Diseases. 81:1675.2-1675

مصطلحات موضوعية: Rheumatology, Immunology, Immunology and Allergy, General Biochemistry, Genetics and Molecular Biology

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::40b62f17faa47c125f8d2d5835e7a685
https://doi.org/10.1136/annrheumdis-2022-eular.2317

المؤلفون: A. Karateev, E. Pogozheva, Alexander Lila, E. Filatova, V N Amirdzhanova

المصدر: Abstracts Accepted for Publication.

مصطلحات موضوعية: medicine.medical_specialty, Visual analogue scale, business.industry, Odds ratio, Osteoarthritis, Type 2 diabetes, medicine.disease, Confidence interval, Synovitis, Internal medicine, medicine, Stage (cooking), business, Body mass index

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::cc4dd4dd05acbb2b3a41d90b5b7fd6c7
https://doi.org/10.1136/annrheumdis-2019-eular.3933

المؤلفون: A. Karateev, E. Pogozheva, V N Amirdzhanova, E. Filatova, Alexander Lila

المصدر: Annals of the Rheumatic Diseases. 80:1109.2-1109

مصطلحات موضوعية: Central sensitization, Rheumatology, business.industry, Rheumatoid arthritis, Immunology, medicine, Immunology and Allergy, medicine.disease, business, General Biochemistry, Genetics and Molecular Biology

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::88537f60b33ca901f1341c302e922583
https://doi.org/10.1136/annrheumdis-2021-eular.3074

المؤلفون: E. Filatova, E. Pogozheva, V N Amirdzhanova, A. Karateev

المصدر: Annals of the Rheumatic Diseases. 80:1162.2-1162

مصطلحات موضوعية: medicine.medical_specialty, Nonsteroidal, business.industry, medicine.drug_class, Immunology, medicine.disease, Gastroenterology, General Biochemistry, Genetics and Molecular Biology, Anti-inflammatory, chemistry.chemical_compound, Rheumatology, chemistry, Internal medicine, Rheumatoid arthritis, medicine, Immunology and Allergy, business

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::11fffb3227116d1891d3befdd4b796ae
https://doi.org/10.1136/annrheumdis-2021-eular.2901

المؤلفون: E. Pogozheva, A. Karateev, V N Amirdzhanova

المصدر: Annals of the Rheumatic Diseases. 80:1160.1-1160

مصطلحات موضوعية: medicine.medical_specialty, business.industry, Immunology, Specialty, Arthritis, Disease, Osteoarthritis, Chiropractic, medicine.disease, General Biochemistry, Genetics and Molecular Biology, Rheumatology, Internal medicine, Back pain, Acupuncture, Immunology and Allergy, Medicine, medicine.symptom, business, Adverse effect

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::b25b56739427314e08d4dc68fb3fd017
https://doi.org/10.1136/annrheumdis-2021-eular.2806

المؤلفون: A. Karateev, Alexander Lila, N. Zagorodniy, E. Pogozheva

المصدر: Annals of the Rheumatic Diseases. 79:1778.2-1778

مصطلحات موضوعية: medicine.medical_specialty, Bursitis, business.industry, Epicondylitis, Immunology, Plantar fasciitis, Soft tissue, Osteoarthritis, medicine.disease, General Biochemistry, Genetics and Molecular Biology, Surgery, medicine.anatomical_structure, Rheumatology, Tendinitis, Orthopedic surgery, medicine, Immunology and Allergy, Rotator cuff, medicine.symptom, business

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::2212add108106b2443704bb6e07145c9
https://doi.org/10.1136/annrheumdis-2020-eular.3969

المؤلفون: E. Pogozheva, A. Karateev, M. Sukhareva, Alexander Lila

المصدر: Annals of the Rheumatic Diseases. 79:1740.2-1740

مصطلحات موضوعية: medicine.medical_specialty, WOMAC, business.industry, Visual analogue scale, Disease duration, Immunology, Placebo-controlled study, Osteoarthritis, Treatment results, medicine.disease, WOMAC index, General Biochemistry, Genetics and Molecular Biology, Rheumatology, medicine, Physical therapy, Immunology and Allergy, business

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::b0b20ea307f9d6319a7acaa0ca03f3c6
https://doi.org/10.1136/annrheumdis-2020-eular.3973

المؤلفون: E. Pogozheva, Alexander Lila, A. Karateev, E. Filatova, V N Amirdzhanova, Nasonov El

المصدر: Annals of the Rheumatic Diseases. 79:974.3-974

مصطلحات موضوعية: medicine.medical_specialty, Central sensitization, Visual analogue scale, business.industry, Immunology, medicine.disease, Gastroenterology, General Biochemistry, Genetics and Molecular Biology, Rheumatology, Internal medicine, Rheumatoid arthritis, medicine, Immunology and Allergy, Severe pain, Anxiety, In patient, medicine.symptom, business, Body mass index, Depression (differential diagnoses)

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::6244d0ed282a08e3e985f5a6af5cce78
https://doi.org/10.1136/annrheumdis-2020-eular.3954

المؤلفون: Alexander Lila, D. Chakieva, V. Mazurov, A. Karateev, V N Amirdzhanova, O. Semagina, I. M. Marusenko, T. Salnikova, M. Semchenkova, Nasonov El, E. Pogozheva, E. Filatova, N. Lapkina, Galina Lukina, R. Samigullina

المصدر: Annals of the Rheumatic Diseases. 79:327.3-327

مصطلحات موضوعية: medicine.medical_specialty, Central sensitization, Tofacitinib, Visual analogue scale, business.industry, Immunology, medicine.disease, General Biochemistry, Genetics and Molecular Biology, Rheumatology, Internal medicine, Rheumatoid arthritis, Neuropathic pain, medicine, Immunology and Allergy, Methotrexate, Brief Pain Inventory, business, medicine.drug, Leflunomide

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::01898f27910df76e52aa317c23909fab
https://doi.org/10.1136/annrheumdis-2020-eular.4029

المؤلفون: E. Pogozheva, Alexander Lila, A. Karateev

المصدر: Back pain, mechanical musculoskeletal problems, local soft tissue disorders.

مصطلحات موضوعية: First episode, Sciatica, medicine.medical_specialty, business.industry, Odds ratio, Affect (psychology), Low back pain, B vitamins, Meloxicam, Internal medicine, medicine, medicine.symptom, Intramuscular injection, business, medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::40a3e9ca59476535e8105c43e4a53e5b
https://doi.org/10.1136/annrheumdis-2018-eular.2920

المؤلفون: V. Amirdzhanova, E. Pogozheva

المصدر: Rheumatoid arthritis – comorbidity and clinical aspects.

مصطلحات موضوعية: education.field_of_study, medicine.medical_specialty, business.industry, Population, medicine.disease, Infliximab, Pharmacotherapy, Quality of life, Rheumatoid arthritis, Internal medicine, Cohort, medicine, Methotrexate, Rituximab, education, business, medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::0e89166a8bec3116495cd600125dcbf6
https://doi.org/10.1136/annrheumdis-2018-eular.3256

المؤلفون: S. Makarov, E. Pogozheva, V N Amirdzhanova

المصدر: Annals of the Rheumatic Diseases. 71:374.2-375

مصطلحات موضوعية: musculoskeletal diseases, medicine.medical_specialty, business.industry, Abatacept, Immunology, Perioperative, medicine.disease, General Biochemistry, Genetics and Molecular Biology, Infliximab, Surgery, chemistry.chemical_compound, Tocilizumab, Rheumatology, chemistry, Rheumatoid arthritis, medicine, Immunology and Allergy, Rituximab, Prospective cohort study, business, medicine.drug, Leflunomide

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::79a51037f843e9f7eae4d5411a57a749
https://doi.org/10.1136/annrheumdis-2012-eular.2641

المؤلفون: E. Pogozheva, V N Amirdzhanova, S. Makarov

المصدر: Annals of the Rheumatic Diseases. 72:A882.2-A882

مصطلحات موضوعية: musculoskeletal diseases, medicine.medical_specialty, business.industry, Immunology, Disease, Perioperative, medicine.disease, General Biochemistry, Genetics and Molecular Biology, Surgery, Venous thrombosis, Rheumatology, Rheumatoid arthritis, medicine, Immunology and Allergy, Rituximab, Methotrexate, business, Prospective cohort study, medicine.drug, Leflunomide

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::41b654c8ace6a7cb5c21bae9bc495dc9
https://doi.org/10.1136/annrheumdis-2013-eular.2633

المؤلفون: S V, Pogozhev, V A, Rogov, E E, Pogozheva

المصدر: Gigiena i sanitariia. (2)

مصطلحات موضوعية: Air Ionization, Electrodes, Aluminum

URL الوصول: https://explore.openaire.eu/search/publication?articleId=pmid________::8e116d19d1f958bfd75132387381aeaf
https://pubmed.ncbi.nlm.nih.gov/2361603

المؤلفون: E E, Pogozheva

المصدر: Vestnik khirurgii imeni I. I. Grekova. 139(11)

مصطلحات موضوعية: Diabetes Complications, Postoperative Care, Acute Disease, Suture Techniques, Carbuncle, Humans, Cellulitis, Middle Aged, Abscess

URL الوصول: https://explore.openaire.eu/search/publication?articleId=pmid________::f0df051746d13e9458bea3c74afaf479
https://pubmed.ncbi.nlm.nih.gov/3330352

المؤلفون: S V, Pogozhev, V A, Rogov, E E, Pogozheva

المصدر: Gigiena i sanitariia. (9)

مصطلحات موضوعية: Aerosols, Photometry, Air Pollutants, Temperature, Dust, Particle Size, Coal Tar, Specimen Handling

URL الوصول: https://explore.openaire.eu/search/publication?articleId=pmid________::50ea729a6badbfc6092daaabc23f0bfa
https://pubmed.ncbi.nlm.nih.gov/2591785